Things to Consider Before Investing in ELV Stocks

Large-cap Health Care company Elevance Health has moved 0.3% so far today on a volume of 119,603, compared to its average of 1,153,979. In contrast, the S&P 500 index moved -0.0%.

Elevance Health trades -22.94% away from its average analyst target price of $569.78 per share. The 18 analysts following the stock have set target prices ranging from $493.0 to $629.0, and on average have given Elevance Health a rating of buy.

If you are considering an investment in ELV, you'll want to know the following:

  • Elevance Health's current price is 54.3% above its Graham number of $284.59, which implies that at its current valuation it does not offer a margin of safety

  • Elevance Health has moved -8.0% over the last year, and the S&P 500 logged a change of 14.0%

  • Based on its trailing earnings per share of 26.88, Elevance Health has a trailing 12 month Price to Earnings (P/E) ratio of 16.3 while the S&P 500 average is 15.97

  • ELV has a forward P/E ratio of 11.9 based on its forward 12 month price to earnings (EPS) of $37.01 per share

  • The company has a price to earnings growth (PEG) ratio of 1.04 — a number near or below 1 signifying that Elevance Health is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 2.71 compared to its sector average of 4.16

  • Elevance Health, Inc. operates as a health benefits company.

  • Based in Indianapolis, the company has 102,300 full time employees and a market cap of $103.47 Billion. Elevance Health currently returns an annual dividend yield of 1.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.